Westport medical technology company BioSig Technologies and its majority-owned subsidiary ViralClear Pharmaceuticals have received FDA approval to proceed with a proposed COVID-19 treatment.
ViralClear can now go forward with its Phase 2 study of merimepodib oral solution in adults who are hospitalized with the coronavirus and either require supplemental oxygen or are on noninvasive ventilation or high-flow oxygen devices.